| Contact Details: |
| 1002 Eastpark Boulevard |
| Cranbury |
| NJ |
| 08512 |
| United States of America |
| Tel: | 609 655 5300 |
| Fax: | 609 655 1755 |
| Email: | |
|
Loading...
|
Recent Publications by Oncotherapeutics Incorporated: |  |
Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell... | 1st September, 2009
| Oncotherapeutics,
| Clin Lymphoma Myeloma. 2009 Aug;9(4):311-5.
DOI Direct Link |
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
BACKGROUND: We conducted a single-arm, multicentre phase 2 study to... | 28th May, 2009
| Oncotherapeutics,
| Eur J Haematol. 2009 Jun;82(6):433-9. Epub 2009 Feb 17.
DOI Direct Link |
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
PURPOSE: Patients with monoclonal gammopathy of undetermined significance... | 17th December, 2008
| Oncotherapeutics, Institute for Myeloma and Bone Cancer Research, James R.
| Clin Cancer Res. 2008 Oct 1;14(19):6289-95.
DOI Direct Link |
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
PURPOSE: This multicenter, open-label, phase I/II dose escalation study... | 15th June, 2007
| Institute for Myeloma and Bone Cancer Research and Oncotherapeutics Inc,
| Clin Cancer Res. 2007 Mar 15;13(6):1762-8.
DOI Direct Link |
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
PURPOSE: Bortezomib has shown synergy with melphalan in preclinical... | 15th March, 2006
| Oncotherapeutics
| J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.
DOI Direct Link |
→View more Oncotherapeutics Incorporated research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 931 times since April 2007, the link to the organisation's website has been followed 0 times
Recent Search Terms used to find this page: Bortezomib ascorbic acid and melphalan BAM therapy for patients with newly diagnosed multiple myeloma an effective and well-tolerated frontline regimen. | oncotherapeutics | Oncotherapeutics | 70 S MAINST CRANBURY NJ | ONCO TH | ONCO TH | Oncotherapeutics | oncotherapeutics profile | oncotherapeutics | Oncotherapeutics | .
Search for more companies in Cranbury
Search for more companies in NJ
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Oncotherapeutics Incorporated
